NAPANEE, Ontario, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Lophos Holdings Inc. ("Lophos") (CSE:MESC), a trailblazer in the production of Lophophora williamsii (peyote), proudly announces a significant stride in the natural health sector. Health Canada's recent recognition of Lophophora williamsii as a Natural Health Product ingredient marks a pivotal moment in the therapeutic use of psychoactive plants, reinforcing Lophos' position at the forefront of this innovative field.

Groundbreaking Achievement

Lophos Pharmaceuticals Corp., a wholly owned subsidiary of Lophos Holdings Inc., operates from Napanee, Ontario, focusing on the cultivation and production of Lophophora williamsii. This decision by Health Canada not only highlights the therapeutic potential of Lophophora williamsii but also demonstrates Lophos' commitment to integrating traditional wisdom with modern science to revolutionize natural health products.

CEO's Vision

Claire Stawnyczy, CEO of Lophos, shared her excitement, stating, "Health Canada's recognition is a validation of our commitment and a significant achievement for the industry. It opens avenues for novel and innovative applications of psychoactive cacti in promoting human well-being." She added, "Being at the forefront of Lophophora williamsii cultivation, we are eager to provide our ethically cultivated cacti to drive innovation in natural health products."

The Future Landscape

Health Canada's decision marks a shift in the perception of psychoactive plants, blending traditional knowledge with cutting-edge science. Lophos stands at the intersection of this evolution, poised to unlock the full potential of Lophophora williamsii.

Strategic Highlights

• Health Canada Recognition: The therapeutic promise of Lophophora williamsii is validated with this approval and listing in the Natural Health Product Ingredient.
• Controlled Substance Dealers License: Ensures responsible cultivation and production at Lophos' Napanee facility.
• Innovation in Natural Health: Lophos leads the way in cultivating sustainable and effective natural health solutions.

Lophos Facility Highlights:

• CSDL licensed facility.
• Authorized to produce mescaline, psilocin, and psilocybin.
• Authorized for the sale, transportation, and distribution of controlled substances including mescaline, psilocin, and psilocybin, DMT, LSD, MDMA, and ketamine.
• Privately owned, state-of-the-art facility spanning 10,000 sq. ft., with 4,000 sq. ft. of dedicated cultivation space.

About Lophos

Lophos Pharmaceuticals Corp., a key subsidiary of Lophos Holdings Inc., is at the forefront of peyote cactus cultivation, research, and sale. Trading under the ticker "MESC" on the Canadian Securities Exchange (CSE), Lophos is committed to the ethical exploration and distribution of peyote, mescaline, psilocin, and psilocybin, as well as contributing to the evolving field of natural health products.

For further inquiries:

Contact: Giselle Barona, Lophos Holdings Inc.
Email: invest@lophos.com
Website:
Phone: 1-833-450-7407

Cautionary Statement

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Lophos' current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the Company's peyote cactus product development. Forward-looking information is based on reasonable assumptions that have been made by Lophos at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Lophos is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Lophos' final long form prospectus dated August 11, 2023, which is available on Lophos's profile at .

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.